Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials

Leukemia

Volumn 11, Issue SUPPL. 3, 1997, Pages 85-88

  Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DELAVIRDINE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

BLOOD LEVEL; CASE REPORT; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; ENVELOPE GENE; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0030808934     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Preston BD et al. Fidelity of HIV-1 reverse transcriptase. Science, 1988; 242: 1168-1171.
2. Tersmette M et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virology, 1988; 62: 2026-2032.